Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02353806|
Recruitment Status : Completed
First Posted : February 3, 2015
Results First Posted : February 6, 2019
Last Update Posted : February 6, 2019
|Condition or disease||Intervention/treatment||Phase|
|Chronic Hypertension in Pregnancy||Drug: Amlodipine besylate||Phase 4|
We plan to evaluate the pharmacokinetics of amlodipine besylate at the time of delivery, to determine if transplacental passage of the drug occurs. We will also examine the drug kinetics in postpartum lactation to establish whether amlodipine is excreted into breast milk. The outcomes of interest are plasma concentration of amlodipine at delivery and the drug concentrations in blood and breast milk over a twenty-hour steady-state period following milk-supply establishment. Fifteen patients already taking 5 mg of amlodipine during pregnancy for the treatment of chronic hypertension will be recruited from the antepartum Obstetric Complications Clinic at Parkland Hospital. Only women who are breastfeeding will be eligible for the study. Patients who elect to participate in the study will continue their amlodipine 5 mg dosing through delivery and into the postpartum period. Maternal blood will be drawn within one hour of delivery and fetal cord blood collected at the time of delivery. Patients will then have blood drawn over a 24 hour period beginning on postpartum day 2 after delivery following administration of their once-daily amlodipine dose. At each blood draw, the patient will also use a breast pump to express breast milk for paired analysis. Both blood and breast milk amlodipine levels will be calculated for all samples. The levels will be used to determine the pharmacokinetics of amlodipine in the peri- and postpartum patient, including concentrations in plasma and breast milk.
In addition to collecting maternal data, a range of clinical information will be collected on each study patient's infant including weight, Apgar scores, hemodynamic parameters, physical examination and hospital course. This information will be used to screen for any potential complications associated with infant exposure to amlodipine. An infant blood sample will also be obtained in conjunction with the routine neonatal blood collection that occurs at 1-2 days of postnatal life and this will be analyzed to determine serum amlodipine concentration in breastfeeding infants.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation|
|Study Start Date :||January 2015|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||September 2016|
Experimental: Pregnant women taking amlodipine
Women already taking amlodipine besylate 5 mg for treatment of chronic hypertension in pregnancy who plan to breastfeed postpartum will be assigned to the single experimental arm.
Drug: Amlodipine besylate
Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
- Area Under the Curve for Amlodipine in the Maternal Serum [ Time Frame: Maternal blood samples will be obtained at 4, 6, 8, 12, 15 and 24 hours after amlodipine dosing ]The time to peak amlodipine concentration in the maternal serum in the peripartum period was be measured.
- Time to Maximal Concentration in the Maternal Serum. [ Time Frame: Maternal blood samples were obtained at 4, 6, 8, 12, 15 and 24 hours after amlodipine dosing ]The time to reach maximal amlodipine concentration in the maternal serum in the peripartum period was measured.
- Maximal Amlodipine Maternal Serum Concentration [ Time Frame: Maternal blood samples were obtained at 4, 6, 8, 12, 15 and 24 hours after amlodipine dosing ]The maximum concentration of amlodipine detected in the maternal serum in the peripartum period was measured.
- Half-life of Amlodipine in Maternal Plasma [ Time Frame: Maternal blood samples were obtained at 4, 6, 8, 12, 15 and 24 hours after amlodipine dosing ]The half-life of amlodipine in the maternal plasma in the peripartum period was measured.
- Clearance Rate of Plasma Amlodipine [ Time Frame: Maternal blood samples were obtained at 4, 6, 8, 12, 15 and 24 hours after amlodipine dosing ]The clearance rate of amlodipine from the maternal plasma was measured.
- Drug Levels/Concentration in Cord Blood (Amlodipine Levels/Concentrations) [ Time Frame: Pair maternal blood sample and cord blood sample will draw within 1 hour of delivery ]Maternal and cord blood amlodipine levels/concentrations will be determined.
- Amlodipine Concentration in Breastmilk [ Time Frame: Breast milk samples were obtained at 4, 6, 8, 12, 15 and 24 hours after amlodipine dosing ]The concentration of amlodipine besylate was measured in breastmilk samples.
- Drug Level/Concentration in Infant Blood (Amlodipine Level/Concentration) [ Time Frame: Infant blood sample drawn at approximately 36 hours of life ]Infant amlodipine level/concentration will be determined.
- Neonatal Birth Weight [ Time Frame: Neonatal weight at the time of birth. ]The neonatal weight at birth was collected.
- Infant Gestational Age at Delivery. [ Time Frame: Gestational age at the time of birth ]The mean gestational age of infants born to mothers taking Amlodipine besylate 5 mg daily was collected.
- Infant Length of Stay. [ Time Frame: Time from birth to hospital discharge ]The length of stay of infants born to women taking amlodipine besylate will be collected.
- Major Infant Complications [ Time Frame: During neonatal hospitalization ]Any major complications experienced by infants born to women taking amlodipine besylate including NICU admission, intraventricular hemorrhage, neonatal seizures, need for respiratory support and apnea were collected.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02353806
|United States, Texas|
|Parkland Health and Hospital System|
|Dallas, Texas, United States, 75235|
|Principal Investigator:||Jamie L Morgan, MD||University of Texas Southwestern Medical Center|